Literature DB >> 19367268

T-cell activation in patients with irritable bowel syndrome.

Lena Ohman1, Stefan Isaksson, Ann-Charlotte Lindmark, Iris Posserud, P-O Stotzer, Hans Strid, Henrik Sjövall, Magnus Simrén.   

Abstract

OBJECTIVES: Irritable bowel syndrome (IBS) has been found to be associated with low-grade immune activation in a subset of patients. We therefore investigated blood and colonic T-cell activity in IBS patients.
METHODS: Blood samples were initially obtained from 74 IBS patients and 30 controls. Supplementary blood samples, to confirm data, were taken from another cohort (26 patients and 14 controls). In addition, colonic biopsies were taken from a third cohort (11 patients and 10 controls). Peripheral blood and colonic mononuclear cells were stimulated with anti-CD3/CD28 antibodies. Proliferation, cytokine secretion, and T-cell phenotype were investigated. IBS symptom severity was assessed.
RESULTS: IBS patients displayed an activated phenotype with increased frequencies of blood T cells expressing CD69 and integrin beta7/HLA-DR. Anti-CD3/CD28-stimulated blood and colonic T cells from IBS patients proliferated less than T cells from controls. IBS patients had an increased polyclonally stimulated T-cell secretion of IL-1beta, which also weakly correlated with increased bowel habit dissatisfaction. Furthermore, despite normal frequencies of CD25high T cells in the blood of IBS patients, lower blood CD25high T-cell frequencies were modestly correlated with more bowel habit dissatisfaction and increased total IBS symptom severity.
CONCLUSIONS: IBS patients have an increased frequency of activated T cells, demonstrated by the expression of activation markers and reduced proliferation in response to restimulation in vitro. The increased level of T-cell activation is consistent with the hypothesis of low-grade immune activation in IBS and may also be involved in symptom generation in IBS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19367268     DOI: 10.1038/ajg.2009.116

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  55 in total

1.  Association of TNFSF15 polymorphism with irritable bowel syndrome.

Authors:  Marco Zucchelli; Michael Camilleri; Anna Nixon Andreasson; Francesca Bresso; Aldona Dlugosz; Jonas Halfvarson; Leif Törkvist; Peter T Schmidt; Pontus Karling; Bodil Ohlsson; Richard H Duerr; Magnus Simren; Greger Lindberg; Lars Agreus; Paula Carlson; Alan R Zinsmeister; Mauro D'Amato
Journal:  Gut       Date:  2011-06-02       Impact factor: 23.059

Review 2.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

3.  Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.

Authors:  Olga Bednarska; Susanna A Walter; Maite Casado-Bedmar; Magnus Ström; Eloísa Salvo-Romero; Maria Vicario; Emeran A Mayer; Åsa V Keita
Journal:  Gastroenterology       Date:  2017-07-13       Impact factor: 22.682

4.  High-sensitive C-Reactive Protein as a Marker for Inflammation in Irritable Bowel Syndrome.

Authors:  Keren Hod; Tamar Ringel-Kulka; Christopher F Martin; Nitsan Maharshak; Yehuda Ringel
Journal:  J Clin Gastroenterol       Date:  2016-03       Impact factor: 3.062

5.  Cytokine-induced alterations of gastrointestinal motility in gastrointestinal disorders.

Authors:  Hirotada Akiho; Eikichi Ihara; Yasuaki Motomura; Kazuhiko Nakamura
Journal:  World J Gastrointest Pathophysiol       Date:  2011-10-15

Review 6.  Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.

Authors:  Lena Ohman; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01-26       Impact factor: 46.802

Review 7.  Inflammation in irritable bowel syndrome: Myth or new treatment target?

Authors:  Emanuele Sinagra; Giancarlo Pompei; Giovanni Tomasello; Francesco Cappello; Gaetano Cristian Morreale; Georgios Amvrosiadis; Francesca Rossi; Attilio Ignazio Lo Monte; Aroldo Gabriele Rizzo; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

8.  Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome.

Authors:  Sean M P Bennet; Annikka Polster; Hans Törnblom; Stefan Isaksson; Sandrine Capronnier; Aurore Tessier; Boris Le Nevé; Magnus Simrén; Lena Öhman
Journal:  Am J Gastroenterol       Date:  2016-06-07       Impact factor: 10.864

9.  Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis.

Authors:  Ji Yong Ahn; Kyung Hun Lee; Chang Hwan Choi; Ju Wan Kim; Hyun Woong Lee; Jeong Wook Kim; Mi Kyung Kim; Gui Young Kwon; Seungbong Han; Seong-Eun Kim; Sung Min Kim; Sae Kyung Chang
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

10.  Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome.

Authors:  Declan P McKernan; Aoife Nolan; Elizabeth K Brint; Siobhain M O'Mahony; Niall P Hyland; John F Cryan; Timothy G Dinan
Journal:  PLoS One       Date:  2009-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.